YF
MCID: YLL002
MIFTS: 60

Yellow Fever (YF)

Categories: Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Yellow Fever

MalaCards integrated aliases for Yellow Fever:

Name: Yellow Fever 12 74 52 58 54 3 43 15 71 32
Urban Yellow Fever 12 71 32
Sylvatic Yellow Fever 12 32
Jungle Yellow Fever 12 71
Yf 52 58
Yellow Fever, Sylvan 12
Bronze John 58
Yellow Jack 58

Characteristics:

Orphanet epidemiological data:

58
yellow fever
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Yellow Fever

CDC : 3 The yellow fever virus is found in tropical and subtropical areas of Africa and South America. The virus is spread to people by the bite of an infected mosquito. Yellow fever is a very rare cause of illness in U.S. travelers. Illness ranges from a fever with aches and pains to severe liver disease with bleeding and yellowing skin (jaundice). Yellow fever infection is diagnosed based on laboratory testing, a person's symptoms, and travel history. There is no medicine to treat or cure infection. To prevent getting sick from yellow fever, use insect repellent, wear long-sleeved shirts and long pants, and get vaccinated.

MalaCards based summary : Yellow Fever, also known as urban yellow fever, is related to west nile virus and encephalitis. An important gene associated with Yellow Fever is EIF2AK4 (Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Sodium citrate and Orange have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotypes are fever and headache

Disease Ontology : 12 A viral infectious disease that results in infection, has material basis in Yellow fever virus, which is transmitted by Aedes, transmitted by Haemagogus, or transmitted by Sabethes species of mosquitoes. The infection has symptom fever, has symptom muscle pain, has symptom backache, has symptom headache, has symptom shivers, has symptom loss of appetite, has symptom jaundice, and has symptom bleeding from the mouth, nose, eyes or stomach leading to vomitus containing blood.

Wikipedia : 74 Yellow fever is a viral disease of typically short duration. In most cases, symptoms include fever,... more...

Related Diseases for Yellow Fever

Diseases related to Yellow Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 399)
# Related Disease Score Top Affiliating Genes
1 west nile virus 32.9 SPCS1 RSAD2 OAS1 CCR5
2 encephalitis 31.3 SPCS1 RSAD2 IL6 CXCL10 CCR5 CCL5
3 chikungunya 31.1 STAT1 RSAD2 OAS1 IL6 CCL5 CCL2
4 japanese encephalitis 31.1 SPCS1 RSAD2 IFNB1 CXCL10 CCL5 CCL2
5 tick-borne encephalitis 31.0 RSAD2 OAS1 IFNB1 CXCL10 CCR5
6 measles 31.0 STAT1 OAS1 IRF7 IL6 IFNB1 CCL5
7 vaccinia 30.9 STAT1 IRF7 IL6 IFNB1 CCR5
8 viral encephalitis 30.9 IL6 CXCL10 CCL5 CCL2
9 dengue hemorrhagic fever 30.9 STAT1 IRF7 IL6 IL4
10 hepatitis c virus 30.9 SPCS1 RSAD2 IRF7 CCR5
11 mumps 30.8 STAT1 IL6 IFNB1 CXCL10
12 rubella 30.8 IL6 IL5 IL4 IFNB1
13 rabies 30.8 STAT1 IRF7 CXCL10 CCL5
14 myelitis 30.7 IL6 IL17A IFNB1
15 leptospirosis 30.7 IL6 IL4 CCL2
16 herpes simplex 30.4 STAT1 OAS1 IRF7 IFNB1 CCL5
17 b-cell growth factor 30.4 IL6 IL4
18 urticaria 30.4 IL6 IL5 IL4
19 west nile encephalitis 30.4 OAS1 CCR5
20 stomatitis 30.4 RSAD2 IL6 IL4
21 cytomegalovirus infection 30.4 IL6 CCL5 CCL2
22 kawasaki disease 30.3 IL6 IL4 IL17A CCL2
23 venezuelan equine encephalitis 30.3 STAT1 IRF7 IFNB1 CXCL10 CCL2
24 filariasis 30.3 IL6 IL5 CCL5
25 crohn's disease 30.3 IL6 IL4 IL17A CCL2
26 q fever 30.2 IL6 IL4 CCL5 CCL2
27 conjunctivitis 30.2 IL6 IL5 IL4 CCL2
28 leprosy 3 30.2 IL6 IL5 IL4 IL17A CXCL10
29 peritonitis 30.2 IL6 IL4 CCL5 CCL2
30 spondyloarthropathy 30.1 IL6 IL4 IL17A CCL2
31 bacterial pneumonia 30.1 IL6 IL17A CXCL1
32 neuritis 30.1 IL6 IL4 CXCL10 CCR5 CCL5 CCL2
33 myocarditis 30.1 IL6 IL4 IL17A CCL2
34 uveitis 30.0 IL6 IL4 IL17A CXCL10 CCR5 CCL2
35 dermatitis 30.0 IL6 IL5 IL4 IL17A CCL5
36 allergic hypersensitivity disease 30.0 SCP2 IL5 IL4 IL17A CCL5
37 hepatitis c 30.0 STAT1 RSAD2 ISG20 IRF7 IFNB1 CXCL10
38 neuromyelitis optica 30.0 IL6 IL5 IL4 IL17A CXCL10
39 respiratory failure 30.0 IL6 IL5 CXCL10 CCL5
40 psoriatic arthritis 29.9 IL6 IL4 IL17A CXCL10 CCL2
41 immune deficiency disease 29.9 STAT1 IL6 IL4 CXCL10 CCR5 CCL5
42 influenza 29.9 STAT1 RSAD2 IRF7 IL6 IFNB1 CXCL10
43 bronchitis 29.8 STAT1 IL6 IL5 IL4 CXCL10 CCL5
44 chagas disease 29.8 IL6 IL4 IL17A CCR5 CCL5 CCL2
45 autoimmune disease 29.8 IL6 IL5 IL4 IL17A IFNB1 CCR5
46 skin disease 29.8 IL6 IL5 IL4 IL17A CXCL10
47 thrombocytopenia 29.8 STAT1 IL6 IL4 IL17A IFNB1 CXCL10
48 malaria 29.7 IRF7 IL6 IL5 IL4 IL17A IFNB1
49 diabetes mellitus, insulin-dependent 29.7 IL6 IL4 IL17A CXCL10 CCR5 CCL2
50 meningitis 29.7 IL6 IL5 IL4 IL17A CXCL1 CCL5

Graphical network of the top 20 diseases related to Yellow Fever:



Diseases related to Yellow Fever

Symptoms & Phenotypes for Yellow Fever

Human phenotypes related to Yellow Fever:

58 31 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
2 headache 58 31 hallmark (90%) Very frequent (99-80%) HP:0002315
3 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
4 proteinuria 58 31 frequent (33%) Frequent (79-30%) HP:0000093
5 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
6 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
7 gastrointestinal hemorrhage 58 31 frequent (33%) Frequent (79-30%) HP:0002239
8 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
9 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
10 jaundice 58 31 frequent (33%) Frequent (79-30%) HP:0000952
11 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
12 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
13 spontaneous abortion 58 31 frequent (33%) Frequent (79-30%) HP:0005268
14 oliguria 58 31 frequent (33%) Frequent (79-30%) HP:0100520
15 menometrorrhagia 58 31 frequent (33%) Frequent (79-30%) HP:0400008
16 hypothermia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002045
17 hypotension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002615
18 encephalitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002383
19 nephropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0000112
20 photophobia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000613
21 dehydration 58 31 occasional (7.5%) Occasional (29-5%) HP:0001944
22 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
23 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
24 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
25 malignant hyperthermia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002047
26 meningitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001287
27 acute hepatic failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0006554
28 lethargy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001254
29 cardiorespiratory arrest 58 31 occasional (7.5%) Occasional (29-5%) HP:0006543

MGI Mouse Phenotypes related to Yellow Fever:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CCL5 CCR5 CXCL10 EIF2AK4 IFNB1 IL17A
2 homeostasis/metabolism MP:0005376 9.97 CCR5 CXCL10 EIF2AK4 IFNB1 IL17A IL4
3 immune system MP:0005387 9.83 CCL2 CCL5 CCR5 CXCL10 EIF2AK4 IFNB1
4 liver/biliary system MP:0005370 9.17 CCR5 EIF2AK4 IL4 IL5 IL6 SCP2

Drugs & Therapeutics for Yellow Fever

Drugs for Yellow Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2 Orange Approved Phase 4
3
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
4 Citrate Phase 4
5 Pharmaceutical Solutions Phase 4
6 Vaccines Phase 4
7 Immunologic Factors Phase 4
8
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
9
Lactitol Investigational Phase 3 585-86-4, 585-88-6 493591
10 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
11 Vitamins Phase 3
12 Micronutrients Phase 3
13 Trace Elements Phase 3
14 retinol Phase 3
15 Retinol palmitate Phase 3
16 Nutrients Phase 3
17 Antioxidants Phase 3
18 Protective Agents Phase 3
19
Aluminum sulfate Approved Phase 1, Phase 2 10043-01-3
20
tannic acid Approved Phase 1, Phase 2 1401-55-4
21
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
22 Antibodies Phase 2
23 Immunoglobulins Phase 2
24 Immunoglobulins, Intravenous Phase 2
25 Rho(D) Immune Globulin Phase 2
26 gamma-Globulins Phase 2
27 Aluminum phosphate Phase 1, Phase 2
28 Antimetabolites Phase 2
29 Hypolipidemic Agents Phase 2
30 Anti-Inflammatory Agents Phase 2
31 Anticholesteremic Agents Phase 2
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
33 Lipid Regulating Agents Phase 2
34 Adjuvants, Immunologic Phase 2
35 MF59 oil emulsion Phase 2
36
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251
37
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
38 Natriuretic Agents Phase 1
39 diuretics Phase 1
40 Antibodies, Monoclonal Phase 1
41 Cathartics Phase 1
42 interferons Phase 1
43 Poly I-C Phase 1
44 Gastrointestinal Agents Phase 1
45 lysine Phase 1
46 Poly ICLC Phase 1
47 Anti-Infective Agents Phase 1
48 Laxatives Phase 1
49 Carboxymethylcellulose Sodium Phase 1
50 Interferon Inducers Phase 1

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina Completed NCT03368495 Phase 4
2 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
3 An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4
4 Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination Recruiting NCT04083430 Phase 4 Yellow Fever Vaccine
5 Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals Recruiting NCT03132311 Phase 4
6 A Randomized, Blinded Non-inferiority Trial on the Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines in Kenya and Uganda Recruiting NCT02991495 Phase 4
7 Yellow Fever Vaccine Immunity After 1 Dose of Vaccine in Children and Adults: a Cohort Study in Non-endemic Area Active, not recruiting NCT02555072 Phase 4
8 01 - GamEvac-Combi-2016 " International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi - Combined Vector-Based Vaccine Against Ebola Virus Disease, 0.5 ml+0.5 ml/Dose " Active, not recruiting NCT03072030 Phase 4
9 Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine Not yet recruiting NCT04059471 Phase 4
10 Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old Not yet recruiting NCT03725618 Phase 4
11 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3
12 The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient Completed NCT01426243 Phase 3
13 A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 Years in Non-Endemic Country(Ies) Completed NCT03342898 Phase 3
14 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
15 Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) Completed NCT01345240 Phase 3
16 Long-Term Assessment at 24 Months Post-Vaccination of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine to Measles Vaccine Given Alone Completed NCT00412516 Phase 3
17 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine. Active, not recruiting NCT02699099 Phase 3
18 A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
19 Randomised, Double-blind, Phase II Evaluation of the Safety and Immunogenicity Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) Completed NCT00982137 Phase 2
20 Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants Completed NCT00436007 Phase 2
21 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2
22 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
23 An Open-label Phase 2a Clinical Trial to Test the Effect of Yellow Fever Vaccination in a Background of Japanese Encephalitis Antibodies. Completed NCT01943305 Phase 2
24 Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
25 A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants Completed NCT02308540 Phase 1, Phase 2
26 Exploring Novel Mechanisms of Vaccine Failure and Induction of Pulmonary Immunity Following Live Attenuated Influenza Vaccination in HIV-infected Individuals: a Pilot Study. Completed NCT02266992 Phase 2
27 A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal Completed NCT01856205 Phase 2 Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
28 Safety, Tolerability, and Immunogenicity Dose-ranging Study of the Investigational Yellow Fever Vacine (vYF) Candidate Vaccine in Adults Recruiting NCT04142086 Phase 1, Phase 2
29 Using Systems Vaccinology to Elucidate the Effects of Anti-inflammatory Therapy on Immune Response After Vaccination With a Live Attenuated Vaccine Recruiting NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
30 A Phase II, Open Label Study to Describe Immune & Transcriptional Responses to MF59 Adjuvanted Trivalent Influenza Vaccine (ATIV) in Healthy 13-24 Month Children and Adults 18-65 Years Active, not recruiting NCT02529904 Phase 2
31 A Phase 2 Randomized, Double-Blind, Controlled Trial of the Safety and Immunogenicity of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Active, not recruiting NCT03614533 Phase 2
32 Randomized Controlled Double-Blind Trial of the Comparative Viremia, Immunogenicity and Safety of a 17-D Live Attenuated Yellow Fever Vaccine (YF-VAX)Given Alone or in Combination With Human Immune Globulin (Gama STAN S/D) Completed NCT00254826 Phase 1
33 Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability,and Immunogenicity of Graded Doses of XRX-001 Yellow Fever 17D, Inactivated Vaccine, Alum Adsorbed in Healthy Adults. Completed NCT00995865 Phase 1
34 A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults Completed NCT02743455 Phase 1 ISA-720
35 Phase 1 First-in-Human, Time Lagged, Single Ascending Dose Study of TY014 in Healthy Adult Volunteers (Safety Arm - 1A) and Sequential Time Lagged, Parallel-Group, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study of TY014 in YF-17D Vaccine Strain-Challenged Healthy Adult Volunteers (Efficacy Arm - 1B) Completed NCT03776786 Phase 1
36 A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects Completed NCT02963909 Phase 1
37 Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine Completed NCT03055000 Phase 1
38 A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA020-00-VP, in Healthy Adult Subjects Completed NCT00300417 Phase 1 VRC-WNVDNA020-00-VP
39 An Open Label Study to Evaluate Innate Immune Responses Induced by a Pattern Recognition Receptor Agonist, Poly-ICLC (Hiltonol), in Healthy Volunteers Completed NCT01299662 Phase 1 Poly ICLC
40 A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever Not yet recruiting NCT03891420 Phase 1 Galidesivir;Placebo
41 Yellow Fever Vaccination Under Low Dose Methotrexate Therapy - a Multi-Center Prospective Observational Controlled Pilot Study Unknown status NCT02383680
42 Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children Unknown status NCT02990182
43 Passive Enhanced Safety Surveillance of the Live Attenuated Yellow Fever Virus Vaccine Stamaril® in Korea Completed NCT03541694
44 Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military, Participants of "Dose-response Study of Yellow Fever Vaccine 17DD Produced by Bio-Manguinhos / Fiocruz" in 2009 Completed NCT03338231
45 The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination Completed NCT00708630
46 Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area Completed NCT03430388
47 Single Cell Transcriptomics for Characterizing the Human Immune Response to Yellow Fever Vaccination Completed NCT03458780 Yellow Fever Vaccine
48 Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults Completed NCT00616356
49 Duration of Immunity After Two Doses of Vaccine Against Yellow Fever in Adults Completed NCT02572518
50 A Clinical Study to Generate an Exploratory Training Set of Data Characterising Clinical Events, Physiological and Metabolic Responses, and Innate and Adaptive Immune Responses Following a Single Subcutaneous Immunisation With Either "Varilrix" Varicella-zoster Vaccine, "Stamaril" Yellow Fever Vaccine or Saline Placebo in Healthy Adults With Evidence of Pre-existing Immunity to Varicella-zoster and no Existing Immunity to Yellow Fever. Completed NCT01765413

Search NIH Clinical Center for Yellow Fever

Cochrane evidence based reviews: yellow fever

Genetic Tests for Yellow Fever

Anatomical Context for Yellow Fever

MalaCards organs/tissues related to Yellow Fever:

40
Liver, Testes, T Cells, Skin, Kidney, Eye, Brain

Publications for Yellow Fever

Articles related to Yellow Fever:

(show top 50) (show all 5770)
# Title Authors PMID Year
1
The structural determination of an insect sterol carrier protein-2 with a ligand-bound C16 fatty acid at 1.35-A resolution. 54 61
12855689 2003
2
Isolation and expression of a sterol carrier protein-2 gene from the yellow fever mosquito, Aedes aegypti. 54 61
12542635 2003
3
Structural characterization and polymorphism analysis of the NS2B-NS3 protease from the 2017 Brazilian circulating strain of Yellow Fever virus. 61
31931019 2020
4
Discovery of an Aedes (Stegomyia) albopictus population and first records of Aedes (Stegomyia) aegypti in Canada. 61
31566765 2020
5
Nanostructured impedimetric lectin-based biosensor for arboviruses detection. 61
31816752 2020
6
Screening for Enhancement of Permethrin Toxicity by Plant Essential Oils Against Adult Females of the Yellow Fever Mosquito (Diptera: Culicidae). 61
32020196 2020
7
Expansion of the Distribution of Aedes albopictus (Diptera: Culicidae): New Records in Northern Argentina and Their Implications From an Epidemiological Perspective. 61
32020186 2020
8
Preparing for yellow fever vaccination. 61
32006508 2020
9
Stablity of yellow fever virus neutralising antibody titres. 61
32006501 2020
10
Stablity of yellow fever virus neutralising antibody titres - Authors' reply. 61
32006502 2020
11
Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis. 61
31859201 2020
12
Influence of landscape composition and configuration on the richness and abundance of potential sylvatic yellow fever vectors in a remnant of Atlantic Forest in the city of São Paulo, Brazil. 61
32027836 2020
13
Modelling epidemics with fractional-dose vaccination in response to limited vaccine supply. 61
31758966 2020
14
Large-Scale Operational Pyriproxyfen Autodissemination Deployment to Suppress the Immature Asian Tiger Mosquito (Diptera: Culicidae) Populations. 61
32006427 2020
15
Small Molecule Inhibitor of ATPase Activity of HSP70 as a Broad-Spectrum Inhibitor against Flavivirus Infections. 61
31967789 2020
16
A Review on Dengue Vaccine Development. 61
32024238 2020
17
Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans. 61
32017766 2020
18
Seroprevalence of yellow fever, dengue, West Nile and chikungunya viruses in children in Teso South Sub-County, Western Kenya. 61
31712089 2020
19
CO2 per se activates carbon dioxide receptors. 61
31760135 2020
20
Male sexual history influences female fertility and re-mating incidence in the mosquito vector Aedes aegypti (Diptera: Culicidae). 61
32032591 2020
21
Discovery of 1,2,4-oxadiazole derivatives as a novel class of noncompetitive inhibitors of 3-hydroxykynurenine transaminase (HKT) from Aedes aegypti. 61
31864777 2020
22
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance. 61
31932713 2020
23
Reduced effectiveness of repellents in a pyrethroid-resistant strain of Aedes aegypti (Diptera: culicidae) and its correlation with olfactory sensitivity. 61
31338960 2020
24
Humanized Mice for Live-Attenuated Vaccine Research: From Unmet Potential to New Promises. 61
31973073 2020
25
Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications. 61
31930750 2020
26
Vaccination Programs for Adults in Europe, 2019. 61
31968652 2020
27
[Travel vaccinations]. 61
31802155 2020
28
Yellow fever control: current epidemiology and vaccination strategies. 61
31938550 2020
29
Repurposing the yellow fever vaccine for intratumoral immunotherapy. 61
31746149 2020
30
Detection of Wild-type Yellow Fever Virus in Breast Milk. 61
31725551 2020
31
Sample Transport Optimization: Mali Pilot Study. 61
32004128 2020
32
Community-Based Surveillance in Côte d'Ivoire. 61
32004127 2020
33
Dengue vaccine development: status and future. 61
31784763 2020
34
Clinical profiles and factors associated with mortality in adults with yellow fever admitted to an intensive care unit in Minas Gerais, Brazil. 61
32004691 2020
35
The response to re-emergence of Yellow Fever in Nigeria, 2017. 61
31935537 2020
36
Perfusion Control for High Cell Density Cultivation and Viral Vaccine Production. 61
31858467 2020
37
Recent sylvatic yellow fever virus transmission in Brazil: the news from an old disease. 61
31973727 2020
38
Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies. 61
32008879 2020
39
Structure-Function of the Yellow Fever Virus Envelope Protein: Analysis of Antibody Epitopes. 61
31682201 2020
40
Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology. 61
31957887 2020
41
Detection of Yellow Fever Virus by Quantitative Real-Time PCR (qPCR). 61
31578688 2020
42
Yellow fever vaccine associated viscerotropic disease in a 62 year old British traveller: a case report. 61
31943039 2020
43
Multi-epitope based vaccine against yellow fever virus applying immunoinformatics approaches. 61
31854239 2020
44
Implementation of Bamboo and Monkey-pot traps for the sampling cavity-breeding mosquitoes in Darién, Panama. 61
31981495 2020
45
Antiviral Effectors and Gene Drive Strategies for Mosquito Population Suppression or Replacement to Mitigate Arbovirus Transmission by Aedes aegypti. 61
31940960 2020
46
Influences of a Prolific Gut Fungus (Zancudomyces culisetae) on Larval and Adult Mosquito (Aedes aegypti)-Associated Microbiota. 61
31757825 2020
47
Geosmin Attracts Aedes aegypti Mosquitoes to Oviposition Sites. 61
31839454 2020
48
Vaccine dose usage and wastage in the Metropolitan Region of Porto Alegre, Rio Grande do Sul, Brazil: a descriptive study, 2015-2017. 61
32022217 2020
49
Urban Spread of Flaviviruses: A New Challenge in Solid-organ Transplant Recipients. 61
31077278 2020
50
Chemosensation: Hate Mosquitoes? Peel Beetroots! 61
31910367 2020

Variations for Yellow Fever

Expression for Yellow Fever

Search GEO for disease gene expression data for Yellow Fever.

Pathways for Yellow Fever

Pathways related to Yellow Fever according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 STAT1 RSAD2 OAS1 ISG20 IRF7 IL6
2
Show member pathways
13.83 STAT1 IL6 IL5 IL4 IL17A CXCL10
3
Show member pathways
13.69 IL6 IL5 IL4 IL17A IFNB1 CXCL10
4
Show member pathways
13.52 STAT1 IL6 IL5 IL4 IL17A IFNB1
5
Show member pathways
13.45 STAT1 IL6 IL5 IL4 IL17A CXCL10
6
Show member pathways
13.34 IL6 IL5 IL4 IL17A CXCL10 CXCL1
7
Show member pathways
13.11 STAT1 RSAD2 OAS1 IRF7 IL6 IFNB1
8
Show member pathways
12.97 STAT1 IRF7 IL6 IFNB1 CXCL1 CCR5
9
Show member pathways
12.89 STAT1 CXCL10 CXCL1 CCR5 CCL5 CCL2
10
Show member pathways
12.83 STAT1 IL6 IL5 IL4 IL17A
11 12.82 STAT1 OAS1 IRF7 IL6 IFNB1 EIF2AK4
12
Show member pathways
12.81 STAT1 RSAD2 OAS1 IRF7 IL6 IFNB1
13
Show member pathways
12.74 IRF7 IL6 IFNB1 CXCL10 CCL5
14
Show member pathways
12.66 STAT1 IL6 IL5 IL4 IL17A CCR5
15
Show member pathways
12.61 STAT1 IL6 IL5 IL4 IL17A
16
Show member pathways
12.61 STAT1 RSAD2 OAS1 ISG20 IRF7 IL6
17
Show member pathways
12.6 STAT1 IL6 IL17A CXCL1 CCL2
18
Show member pathways
12.59 STAT1 RSAD2 OAS1 ISG20 IRF7 IFNB1
19 12.54 STAT1 RSAD2 OAS1 IRF7 IL4 IL17A
20
Show member pathways
12.4 STAT1 IL6 IL5 IL4 IFNB1
21
Show member pathways
12.4 IL6 CXCL10 CXCL1 CCR5 CCL5 CCL2
22
Show member pathways
12.34 IL6 IL5 IL4 IL17A CXCL10 CXCL1
23
Show member pathways
12.31 IL6 IL4 CCL5 CCL2
24
Show member pathways
12.24 STAT1 IL6 IL4 IFNB1 CXCL10
25 12.18 STAT1 OAS1 IRF7 IL6 IFNB1 CXCL1
26 12.09 IL6 IL4 CXCL10 CXCL1 CCL2
27
Show member pathways
12.06 STAT1 RSAD2 OAS1 ISG20 IRF7 IL6
28 12.05 STAT1 IL6 IL4 IL17A CCL2
29 12.02 IL6 IFNB1 CXCL10 CXCL1 CCL5 CCL2
30 11.98 IRF7 IL6 IFNB1 CXCL1
31 11.92 IL6 IL17A CXCL1 CCL5 CCL2
32 11.91 STAT1 IL6 IFNB1 CCR5
33 11.87 IL6 IL5 IL4
34 11.86 STAT1 IL6 IL5 IL4
35
Show member pathways
11.84 IL6 IL17A CXCL1
36 11.77 IL5 IL4 IL17A
37 11.74 IRF7 IL5 IFNB1
38 11.71 IL6 IL5 IL4 CCL5 CCL2
39 11.65 IL6 IL4 IL17A CXCL10 CXCL1 CCL5
40 11.46 STAT1 OAS1 IFNB1 CXCL10
41 11.37 IL6 IL5 IL4 IL17A
42 11.29 IL6 IL5 IL4 IFNB1 CXCL1
43 11.19 IL6 IL4 CXCL10 CXCL1 CCR5 CCL5
44
Show member pathways
11.18 STAT1 OAS1 IRF7
45 11.05 IL6 IL5 IL4 IL17A CXCL10 CXCL1

GO Terms for Yellow Fever

Cellular components related to Yellow Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 IL6 IL5 IL4 IL17A IFNB1 CXCL10
2 extracellular region GO:0005576 9.32 OAS1 IL6 IL5 IL4 IL17A IFNB1
3 signal peptidase complex GO:0005787 9.16 SPCS3 SPCS1

Biological processes related to Yellow Fever according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.23 STAT1 IL6 IL5 IL4 CXCL10 CXCL1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 STAT1 IRF7 IL6 IL4 IL17A IFNB1
3 viral process GO:0016032 10.04 STAT1 RSAD2 IRF7 EIF2AK4 CCR5
4 inflammatory response GO:0006954 10.01 IL6 IL5 IL17A CXCL10 CXCL1 CCR5
5 MAPK cascade GO:0000165 9.96 IL5 CCR5 CCL5 CCL2
6 cell surface receptor signaling pathway GO:0007166 9.94 IFNB1 CXCL10 CCR5 CCL2
7 cell-cell signaling GO:0007267 9.93 IL17A CXCL10 CCR5 CCL5
8 cellular response to lipopolysaccharide GO:0071222 9.91 IL6 CXCL10 CXCL1 CCR5 CCL2
9 chemotaxis GO:0006935 9.89 CXCL10 CXCL1 CCR5 CCL5 CCL2
10 defense response GO:0006952 9.88 STAT1 IFNB1 CXCL10 CXCL1 CCR5
11 immune response GO:0006955 9.85 OAS1 IL6 IL5 IL4 IL17A CXCL10
12 cell chemotaxis GO:0060326 9.84 CXCL10 CCR5 CCL5 CCL2
13 cellular response to interleukin-1 GO:0071347 9.83 IL17A CCL5 CCL2
14 neutrophil chemotaxis GO:0030593 9.83 CXCL10 CXCL1 CCL5 CCL2
15 chemokine-mediated signaling pathway GO:0070098 9.83 CXCL10 CXCL1 CCR5 CCL5 CCL2
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 IL6 IL4 CCL5
17 interferon-gamma-mediated signaling pathway GO:0060333 9.8 STAT1 OAS1 IRF7
18 type I interferon signaling pathway GO:0060337 9.8 STAT1 RSAD2 OAS1 ISG20 IRF7 IFNB1
19 response to virus GO:0009615 9.8 RSAD2 OAS1 ISG20 IRF7 IFNB1 CXCL10
20 cellular response to organic cyclic compound GO:0071407 9.79 STAT1 CCL5 CCL2
21 positive regulation of T cell proliferation GO:0042102 9.78 IL6 IL4 CCL5
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 STAT1 IL6 CCL5
23 negative regulation of viral genome replication GO:0045071 9.77 RSAD2 OAS1 ISG20 IFNB1 CCL5
24 humoral immune response GO:0006959 9.76 IL6 IFNB1 CCL2
25 monocyte chemotaxis GO:0002548 9.74 IL6 CCL5 CCL2
26 positive regulation of JAK-STAT cascade GO:0046427 9.72 IL6 IL5 CCL5
27 macrophage chemotaxis GO:0048246 9.67 CCL5 CCL2
28 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL6 IL5
29 positive regulation of interferon-alpha production GO:0032727 9.66 STAT1 IRF7
30 signal peptide processing GO:0006465 9.66 SPCS3 SPCS1
31 protein targeting to ER GO:0045047 9.65 SPCS3 SPCS1
32 negative regulation of macrophage apoptotic process GO:2000110 9.63 IRF7 CCR5 CCL5
33 defense response to virus GO:0051607 9.61 STAT1 RSAD2 OAS1 ISG20 IRF7 IL6
34 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.59 RSAD2 IL6
35 viral protein processing GO:0019082 9.56 SPCS3 SPCS1
36 cytokine-mediated signaling pathway GO:0019221 9.36 STAT1 IL6 IL5 IL4 IL17A IFNB1

Molecular functions related to Yellow Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL6 IL5 IL4 CXCL1
2 cytokine activity GO:0005125 9.28 IL6 IL5 IL4 IL17A IFNB1 CXCL10
3 CCR5 chemokine receptor binding GO:0031730 9.26 STAT1 CCL5
4 chemokine activity GO:0008009 9.26 CXCL10 CXCL1 CCL5 CCL2

Sources for Yellow Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....